GO:0001733 galactosylceramide sulfotransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001733 galactosylceramide sulfotransferase activity catalyzes the transfer of sulfate from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to galactosylceramide, producing galactosylceramide sulfate (sulfatide) and adenosine 3',5'-bisphosphate.
• This enzymatic activity is essential for the synthesis of sulfatide, a major glycosphingolipid of the myelin sheath in the central and peripheral nervous systems [1,2].
• The enzyme is developmentally regulated, with peak activity during active myelination in the brain, as shown in rodent studies [2,3].
• Hormones and growth factors, including glucocorticoids, insulin, and PPARα agonists, modulate galactosylceramide sulfotransferase activity [4,7,8].
• Deficiency in sulfatide synthesis due to reduced galactosylceramide sulfotransferase activity contributes to neuroinflammation and cognitive impairment, linking it to Alzheimer's disease-like pathology.
• Altered activity of this enzyme has been observed in renal cancer cells and may influence glycolipid sulfotransferase regulation in cancer.
Description
Galactosylceramide sulfotransferase (EC 2.8.2.11) is the enzyme responsible for the final step in sulfatide biosynthesis, transferring a sulfate group from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to galactosylceramide. This activity is encoded by the gene CST (also known as GAL3ST1) in humans and is highly expressed in myelinating glia, particularly oligodendrocytes and Schwann cells [1,2]. Sulfatide, the product of this reaction, is a major component of the myelin sheath and plays critical roles in myelin stability, axon-glia interactions, and neuronal signaling. Research over several decades has established that galactosylceramide sulfotransferase activity is developmentally regulated, with peak levels coinciding with active myelination in the brain [2,3]. Studies in myelin-deficient jimpy mice revealed reduced enzyme activity, linking it to myelin disorders. The activity is also modulated by hormones and growth factors, including glucocorticoids and insulin, suggesting a complex regulatory network [4,7]. More recently, adult-onset sulfatide deficiency has been shown to cause Alzheimer's disease-like neuroinflammation and cognitive impairment, highlighting the importance of this enzyme in neurodegeneration. Given its central role in lipid metabolism and myelin biology, galactosylceramide sulfotransferase activity is a key target for researchers studying demyelinating diseases, neurodegenerative disorders, and cancer. Understanding its regulation and function requires robust experimental models, including CRISPR-engineered cell lines and animal models [1,5,8].
galactosylceramide sulfotransferase activity At A Glance
| GO ID | GO:0001733 |
|---|---|
| GO term | galactosylceramide sulfotransferase activity |
| Ontology | molecular_function |
| Synonym | cerebroside sulfotransferase activity; galactocerebroside sulfotransferase activity; GSase; 3'-phosphoadenosine-5'-phosphosulfate-cerebroside sulfotransferase activity |
| Major function | Catalyzes the transfer of sulfate from PAPS to galactosylceramide, producing sulfatide and adenosine 3',5'-bisphosphate |
| Reaction | 3'-phosphoadenosine 5'-phosphosulfate + a galactosylceramide = adenosine 3',5'-bisphosphate + a galactosylceramide sulfate |
| Cofactor | 3'-phosphoadenosine 5'-phosphosulfate (PAPS) as sulfate donor |
| Localization | Golgi membrane (as a type II transmembrane protein) |
| Tissue specificity | Highly expressed in myelinating glia (oligodendrocytes, Schwann cells) and kidney |
What Is GO:0001733?
Galactosylceramide sulfotransferase activity (GO:0001733) is a molecular function defined as the catalysis of the reaction: 3'-phosphoadenosine 5'-phosphosulfate (PAPS) + a galactosylceramide = adenosine 3',5'-bisphosphate + a galactosylceramide sulfate. In simpler terms, it is the enzyme activity that attaches a sulfate group to galactosylceramide, forming sulfatide, a critical lipid in myelin. This activity is synonymous with cerebroside sulfotransferase (CST) and galactocerebroside sulfotransferase, among other names.
Why Is galactosylceramide sulfotransferase activity Important in Cell Biology?
Galactosylceramide sulfotransferase activity is essential for the biosynthesis of sulfatide, a major glycosphingolipid of the myelin sheath. Sulfatide is critical for myelin stability, axon-glia interactions, and neuronal signaling. Dysregulation of this activity leads to sulfatide deficiency, which has been linked to neuroinflammation, cognitive impairment, and demyelinating diseases [1,2]. Additionally, altered enzyme activity has been observed in renal cancer, suggesting a role in cancer biology. Therefore, understanding this activity is crucial for developing therapies for neurological disorders and cancers.
• Essential for myelin sheath formation and maintenance in the central and peripheral nervous systems [1,2].
• Deficiency causes Alzheimer's disease-like neuroinflammation and cognitive impairment in adult-onset models.
• Reduced activity is associated with myelin-deficient jimpy mice, a model for demyelinating diseases.
• Developmentally regulated, with peak activity during active myelination [2,3].
• Modulated by glucocorticoids, insulin, and PPARα agonists, linking it to metabolic and hormonal signaling [4,7,8].
• Altered in human renal cancer cells, suggesting a role in cancer progression.
• Target of the PGRMC1 antagonist AG-205, which inhibits synthesis of galactosylceramide and sulfatide.
• Potential biomarker for sulfatide-related disorders and therapeutic target for myelin repair [1,6].
Molecular Mechanism of galactosylceramide sulfotransferase activity
Substrate Binding and Sulfate Transfer
In simple terms: The enzyme grabs a sulfate group from PAPS and attaches it to galactosylceramide.
Galactosylceramide sulfotransferase catalyzes the transfer of a sulfate group from the donor 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to the acceptor galactosylceramide, yielding sulfatide and adenosine 3',5'-bisphosphate. The enzyme is a type II transmembrane protein localized to the Golgi apparatus, where it encounters its lipid substrate. The reaction is highly specific for galactosylceramide, and the product sulfatide is a major component of myelin [1,2].
Cofactor Requirement: PAPS
In simple terms: PAPS is the sulfate donor that the enzyme needs to work.
The enzyme requires 3'-phosphoadenosine 5'-phosphosulfate (PAPS) as the sulfate donor. PAPS is synthesized in the cytosol and transported into the Golgi lumen, where sulfation occurs. The reaction produces adenosine 3',5'-bisphosphate as a byproduct. This dependence on PAPS links galactosylceramide sulfotransferase activity to cellular sulfate metabolism.
Developmental and Hormonal Regulation
In simple terms: The enzyme's activity changes with brain development and in response to hormones.
Galactosylceramide sulfotransferase activity is developmentally regulated, with peak levels during active myelination in the brain. Studies in mice and rats show that activity increases postnatally and then declines [2,3]. Glucocorticoids can modulate enzyme activity in rat brain, and insulin and growth factors regulate it in cultured oligodendrocytes. PPARα agonists enhance cerebroside sulfotransferase gene expression in murine organs.
Inhibition by PGRMC1 Antagonist
In simple terms: A drug called AG-205 can block the synthesis of galactosylceramide and sulfatide.
The PGRMC1 antagonist AG-205 inhibits the synthesis of galactosylceramide and sulfatide, indicating that PGRMC1 is involved in regulating this pathway. This suggests that galactosylceramide sulfotransferase activity can be modulated pharmacologically, offering potential therapeutic avenues for conditions linked to sulfatide metabolism.
Key Genes Involved in GO:0001733 galactosylceramide sulfotransferase activity
The following genes and proteins are directly involved in galactosylceramide sulfotransferase activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GAL3ST1 (CST) | Encodes galactosylceramide sulfotransferase, the enzyme that catalyzes the reaction | Central to sulfatide biosynthesis; knockout models show myelin abnormalities [1,2] |
| ARS A (ARSA) | Arylsulfatase A, degrades sulfatide | Mutations cause metachromatic leukodystrophy; activity measured alongside CST [2,3] |
| PGRMC1 | Progesterone receptor membrane component 1, regulates lipid synthesis | Antagonist AG-205 inhibits galactosylceramide and sulfatide synthesis |
| PPARα (PPARA) | Peroxisome proliferator-activated receptor alpha, transcription factor | Mediates enhancement of cerebroside sulfotransferase gene expression |
| Insulin receptor | Mediates insulin signaling | Insulin regulates cerebroside sulfotransferase activity in oligodendrocytes |
| Glucocorticoid receptor (NR3C1) | Mediates glucocorticoid signaling | Glucocorticoids affect galactosylceramide sulfotransferase activity in rat brain |
| UDP-galactose:ceramide galactosyltransferase (UGT8) | Synthesizes galactosylceramide, the substrate for CST | Upstream of CST; knockout reduces sulfatide |
| PAPS synthase (PAPSS1/2) | Synthesizes PAPS, the sulfate donor | Provides substrate for sulfation; links to sulfate metabolism |
| Myelin basic protein (MBP) | Major myelin protein | Co-regulated with CST during myelination |
| Proteolipid protein (PLP1) | Major myelin protein | Co-regulated with CST during myelination |
| CNPase (CNP) | Myelin enzyme | Marker of myelination; co-expressed with CST |
| Sox10 | Transcription factor for myelinating glia | Regulates genes involved in myelination, including CST |
| Olig1/2 | Transcription factors for oligodendrocyte differentiation | May regulate CST expression during development |
| Fyn kinase | Signaling kinase in oligodendrocytes | May modulate CST activity via growth factor signaling |
| Akt/PI3K | Signaling pathway | Insulin/growth factor regulation of CST may involve PI3K/Akt |
| ERK/MAPK | Signaling pathway | Growth factor regulation of CST may involve MAPK |
| SREBP | Lipid transcription factor | May regulate lipid synthesis genes including CST |
| NF-κB | Inflammatory transcription factor | Sulfatide deficiency triggers neuroinflammation via NF-κB |
How Is galactosylceramide sulfotransferase activity Regulated?
Galactosylceramide sulfotransferase activity is regulated at multiple levels. Developmentally, activity peaks during active myelination and declines thereafter [2,3]. Hormonal regulation includes glucocorticoids, which can modulate activity in rat brain, and insulin, which regulates activity in cultured oligodendrocytes. Growth factors also influence activity. At the transcriptional level, PPARα agonists enhance cerebroside sulfotransferase gene expression in murine organs. Additionally, the PGRMC1 antagonist AG-205 inhibits synthesis of galactosylceramide and sulfatide, suggesting regulation by PGRMC1. These regulatory mechanisms ensure proper sulfatide levels for myelin function.
galactosylceramide sulfotransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GAL3ST1 (CST) | Alzheimer's disease-like neuroinflammation, cognitive impairment | Knockout mouse, overexpression in cell lines |
| GAL3ST1 (CST) | Demyelinating diseases (e.g., metachromatic leukodystrophy) | Jimpy mouse model, patient-derived iPSCs |
| GAL3ST1 (CST) | Renal cancer | Renal cancer cell lines with modulated CST expression |
| PGRMC1 | Lipid metabolism disorders | AG-205 treatment in cell culture |
| PPARα | Metabolic regulation of sulfatide synthesis | PPARα agonist treatment in mice |
Neurodegeneration and Alzheimer's Disease
Adult-onset sulfatide deficiency, caused by reduced galactosylceramide sulfotransferase activity, is sufficient to cause Alzheimer's disease-like neuroinflammation and cognitive impairment in mice. This links the enzyme directly to neurodegenerative pathology. Sulfatide deficiency triggers neuroinflammation, which is a hallmark of Alzheimer's disease.
Demyelinating Diseases
Reduced galactosylceramide sulfotransferase activity is observed in myelin-deficient jimpy mice, a model for demyelinating diseases. Proper sulfatide synthesis is essential for myelin stability, and its deficiency leads to myelin abnormalities [1,2]. This suggests that the enzyme is critical for myelin maintenance and that its dysfunction may contribute to demyelinating conditions such as multiple sclerosis.
Cancer
Altered glycolipid sulfotransferase activity has been studied in human renal cancer cells, indicating a potential role in cancer biology. The regulation of sulfotransferase activity in cancer cells may affect glycolipid metabolism and cell behavior.
From galactosylceramide sulfotransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of CST knockout on myelin and behavior? | GAL3ST1 knockout mouse |
| How does point mutation in CST affect enzyme activity? | CRISPR point-mutation knock-in cell lines (e.g., HEK293) |
| Can overexpression of CST rescue sulfatide deficiency? | CST overexpression in oligodendrocyte precursor cells |
| What is the role of CST in cancer cell proliferation? | CST knockdown in renal cancer cell lines |
| How does PPARα regulate CST expression? | PPARα agonist treatment in wild-type and PPARα knockout mice |
| Does PGRMC1 regulate CST activity? | PGRMC1 antagonist AG-205 in cell culture |
How to Study the galactosylceramide sulfotransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioactive enzyme assay | CST enzymatic activity | Tissue homogenates, cell lysates [2,3] |
| RT-qPCR | CST mRNA expression | Gene regulation studies [7,8] |
| Western blot | CST protein levels | Protein expression analysis |
| Lipidomics (LC-MS) | Sulfatide levels | Metabolic studies [1,6] |
| CRISPR knockout | Loss-of-function effects | Functional studies |
| CRISPR knock-in | Point mutations or tags | Structure-function analysis |
| Immunohistochemistry | CST localization in tissues | Myelin studies |
| Behavioral tests | Cognitive function | Neurodegeneration models |
Enzymatic Activity Assays
Galactosylceramide sulfotransferase activity is typically measured using radiolabeled PAPS (35S-PAPS) and galactosylceramide as substrates, followed by separation of the radiolabeled sulfatide product by thin-layer chromatography or scintillation counting [2,3]. This method allows direct quantification of enzyme activity in tissue homogenates or cell lysates.
Gene Expression Analysis
RNA-seq or quantitative RT-PCR can measure CST (GAL3ST1) mRNA levels in tissues or cells. This is useful for assessing transcriptional regulation by hormones, growth factors, or PPARα agonists [7,8]. Western blotting can detect CST protein levels.
Lipidomics and Mass Spectrometry
Mass spectrometry-based lipidomics can quantify sulfatide levels as a readout of CST activity in cells or tissues. This approach is valuable for studying changes in sulfatide metabolism in disease models [1,6].
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 can be used to generate knockout, point-mutation, or knock-in models to study the function of CST and its regulators. For example, knockout of GAL3ST1 in cell lines or mice can reveal its role in sulfatide synthesis and myelin biology.
How CRISPR Can Be Used to Study GO:0001733 galactosylceramide sulfotransferase activity
Knockout
CRISPR-Cas9 knockout of GAL3ST1 (CST) eliminates galactosylceramide sulfotransferase activity, leading to sulfatide deficiency. This model is used to study the consequences of sulfatide loss in myelin and neurodegeneration. Knockout mice exhibit myelin abnormalities and neuroinflammation.
Point Mutation
CRISPR point mutation can introduce specific amino acid substitutions in CST to study catalytic residues or regulatory sites. This helps dissect the enzyme's mechanism and identify critical residues for PAPS binding or catalysis.
Knock-in
Knock-in of tagged CST (e.g., FLAG or GFP) allows visualization and purification of the enzyme for interaction studies. Knock-in of disease-associated mutations can model human disorders.
Overexpression
Overexpression of CST in cell lines or transgenic mice increases sulfatide synthesis, useful for gain-of-function studies and for testing rescue of sulfatide deficiency. This can be achieved via CRISPR activation or lentiviral delivery.
How EDITGENE Supports galactosylceramide sulfotransferase activity Research
Researchers studying galactosylceramide sulfotransferase activity-related genes often need to determine whether a candidate gene is causally involved in sulfatide metabolism, myelin biology, or disease. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for galactosylceramide sulfotransferase activity research.
Frequently Asked Questions About galactosylceramide sulfotransferase activity
What is galactosylceramide sulfotransferase activity?
It is the enzyme activity that transfers a sulfate group from PAPS to galactosylceramide, producing sulfatide, a major myelin lipid.
What genes are involved in galactosylceramide sulfotransferase activity?
The primary gene is GAL3ST1 (also known as CST), which encodes the enzyme. Other genes include ARSA, PGRMC1, and PPARA, which regulate or interact with the pathway [1,2,6,8].
What is the role of galactosylceramide sulfotransferase in myelin?
It synthesizes sulfatide, a critical component of the myelin sheath that ensures myelin stability and proper nerve conduction [1,2].
How is galactosylceramide sulfotransferase activity regulated?
It is regulated developmentally, hormonally (glucocorticoids, insulin), and transcriptionally (PPARα). PGRMC1 also modulates the pathway [2,4,6,7,8].
What diseases are associated with galactosylceramide sulfotransferase deficiency?
Sulfatide deficiency due to reduced activity causes Alzheimer's disease-like neuroinflammation and cognitive impairment, and is linked to demyelinating diseases [1,2].
How can I measure galactosylceramide sulfotransferase activity?
Radioactive enzyme assays using 35S-PAPS and galactosylceramide are standard, along with lipidomics to quantify sulfatide [2,3].
Can CRISPR be used to study galactosylceramide sulfotransferase?
Yes, CRISPR knockout, point mutation, and knock-in models are powerful tools to dissect the enzyme's function and regulation.
What is the difference between galactosylceramide sulfotransferase and arylsulfatase A?
Galactosylceramide sulfotransferase synthesizes sulfatide, while arylsulfatase A degrades it. Both are important for sulfatide homeostasis [2,3].
Is galactosylceramide sulfotransferase involved in cancer?
Altered activity has been observed in renal cancer cells, suggesting a potential role in cancer biology.
What model organisms are used to study galactosylceramide sulfotransferase?
Mice, rats, and cultured oligodendrocytes are commonly used. Jimpy mice are a model for myelin deficiency [2,3,7].
Conclusion
Galactosylceramide sulfotransferase activity (GO:0001733) is a critical enzymatic function for sulfatide biosynthesis and myelin integrity. Its dysregulation is linked to neurodegenerative and demyelinating diseases, making it a key target for research. Advances in CRISPR-based models and lipidomics will continue to unravel its regulation and therapeutic potential.
References
- 1. Qiu S et al.. 2021. Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer's disease-like neuroinflammation and cognitive impairment.. Mol Neurodegener 16(1):64 PMID: 34526055
- 2. Burkart T et al.. 1981. Net sulfatide synthesis, galactosylceramide sulfotransferase and arylsulfatase A activity in the developing cerebrum and cerebellum of normal mice and myelin-deficient jimpy mice.. Biochim Biophys Acta 673(3):351-8 PMID: 6112019
- 3. van der Pal RH et al.. 1990. Galactosylceramide sulfotransferase, arylsulfatase A and cerebroside sulfatase activity in different regions of developing rat brain.. Biochim Biophys Acta 1043(1):91-6 PMID: 1968763
- 4. Meyer JS et al.. 1982. Effect of glucocorticoids on galactosylceramide sulfotransferase activity in rat brain.. Brain Res 252(1):192-6 PMID: 6959686
- 5. Yabunaka N. 1995. [Studies on the regulation of glycolipid sulfotransferase activity in human renal cancer cells].. Hokkaido Igaku Zasshi 70(2):289-300 PMID: 7774881
- 6. Wang-Eckhardt L et al.. 2021. The PGRMC1 Antagonist AG-205 Inhibits Synthesis of Galactosylceramide and Sulfatide.. Cells 10(12) PMID: 34944026
- 7. Fressinaud C et al.. 1989. Regulation of cerebroside sulfotransferase activity in cultured oligodendrocytes: effect of growth factors and insulin.. J Cell Physiol 141(3):667-74 PMID: 2687300
- 8. Nakajima T et al.. 2013. Peroxisome proliferator-activated receptor α mediates enhancement of gene expression of cerebroside sulfotransferase in several murine organs.. Glycoconj J 30(6):553-60 PMID: 23065187
